Research Topics
| Richard M ElledgeSummaryAffiliation: Baylor College of Medicine Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcomeGrazia Arpino
Breast Center at Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
Breast Cancer Res 6:R149-56. 2004..At present, management decisions should be based on individual patient and tumor biologic characteristics, and not on lobular histology...
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistanceGrazia Arpino
Breast Center, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA
J Natl Cancer Inst 97:1254-61. 2005..As in laboratory models, lack of PR expression in ER+ tumors may be a surrogate marker of aberrant growth factor signaling that could contribute to the tamoxifen resistance observed in these tumors...- Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancersYee-Lu Tham
Breast Center and the Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
Breast Cancer Res Treat 94:279-84. 2005..Docetaxel acts therapeutically by inducing apoptosis and this can be used as a marker of response... - Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancerSyed K Mohsin
Breast Center at Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
Breast Cancer Res Treat 94:205-11. 2005..Proliferation, determined by Ki67 staining, was not significantly changed. Clinical trials of this type are difficult to carry out and modifications in trial design are needed to make this process more efficient... 
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesMothaffar F Rimawi
Department of Medicine, Baylor College of Medicine, Houston, TX, USA
Cancer 116:1234-42. 2010..We hypothesized that EGFR expression in human breast tumors, when centrally and uniformly assessed, is associated with an aggressive phenotype and resistance to systemic therapy...- HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group studyGrazia Arpino
Breast Center, Baylor College of Medicine, Methodist Hospital, Houston, Texas, USA
Clin Cancer Res 10:5670-6. 2004.... - Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotypeDang M Nguyen
Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
Clin Cancer Res 12:5047-54. 2006..CONCLUSION: This study is one of the largest molecular analyses of IBC. Both IBC and non-IBC are genetically heterogeneous with consistent differences in the molecular phenotype of IBC... - Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databasesValerie-Jeanne Bardou
Breast Center at Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
J Clin Oncol 21:1973-9. 2003..Therefore, PgR status should be taken into account when discussing RR reductions expected from endocrine treatment with individual patients... - Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcomeGrazia Arpino
Breast Center at Baylor College of Medicine, Houston, Texas 77030, USA
Cancer 94:2119-27. 2002..Good local control can be achieved by lumpectomy with radiation or by simple mastectomy. Axillary lymph node dissection is not helpful in clinical management... - Association of surgery with improved survival in stage IV breast cancer patientsD Kay Blanchard
Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA
Ann Surg 247:732-8. 2008..This study aims to examine the role of surgery in patients with stage IV breast cancer... - Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumorJenny Chang
Breast Center at Baylor College of Medicine, Houston, Texas, USA
Cancer 97:545-53. 2003..Therefore, the authors tested the hypothesis that the characteristics of primary breast tumors are important determinants of prognosis and survival in patients with metastatic breast carcinoma... - The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopauseYee Lu Tham
Breast Care Center, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas, 77030, USA
J Support Oncol 4:295-8, 304. 2006..05). More emphasis must be given to educating breast cancer survivors with chemotherapy-induced menopause about bone health and its maintenance. Approved therapies to prevent osteoporosis probably are underused in this population... - Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary resultsAndrea E Van Pelt
Department of Surgery, Methodist Hospital, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Clin Breast Cancer 4:348-53. 2003..A high rate of brain metastasis was noted, particularly in patients with baseline metastatic disease... - Lobular neoplasia on core-needle biopsy--clinical significanceGrazia Arpino
Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
Cancer 101:242-50. 2004..Thus, like patients with ADH, patients with LN on core biopsy could be considered candidates for surgical excision, which would allow full assessment of breast carcinoma risk and thereby facilitate the planning of prevention strategies... - Premalignant and in situ breast disease: biology and clinical implicationsGrazia Arpino
Breast Care Center, Baylor College of Medicine, The Methodist Hospital, Houston, Texas 77030, USA
Ann Intern Med 143:446-57. 2005..Current clinical management is heterogeneous and depends on histologic examination and individual patient factors. Options for breast cancer risk reduction and prevention are available... - A roundtable discussion of aromatase inhibitors as therapy for breast cancerD Craig Allred
Baylor College of Medicine, Houston, Texas, USA
Breast J 9:213-22. 2003..Finally, recent results suggest that anastrozole may be superior to tamoxifen as adjuvant therapy for early stage disease in postmenopausal women with hormone-responsive disease... - Tales from a targeted therapyRichard M Elledge
J Clin Oncol 24:1323-5. 2006 - Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trialsAnthony Howell
Department of Medical Oncology, Cancer Research UK, Christie Hospital, Manchester, United Kingdom
Cancer 104:236-9. 2005..The authors reported the overall survival results from these studies...
Research Grants
- NSABP Participating SitesJenny Chang; Fiscal Year: 2007....